TAA-T Cell

Phase 1

CChildren's National Research Institute

TAA-T Cell is one of 4 therapeutic programs targeting Diffuse Midline Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diffuse Midline GliomaNot yet recruiting

Diffuse Midline GliomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Diffuse Midline Glioma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Preclinical

1 2

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 3

TAA-T Cell

CChildren's National Research Institute

Phase 1

1 4

PEP-CMV Vaccine

WWashington University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1Not yet recruiting

Diffuse Midline Glioma

NCT07796061

Clinical

Trials by Indication[1]

Diffuse Midline Glioma1 trial

A Safety and Feasibility Study to Evaluate Blood-Brain Barrier Disruption Using Exablate MR-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With Preferentially Expressed Antigen of Melanoma (PRAME), Survivin, and Wilms Tumor 1 (WT1)-Targeting Tumor Associated Antigen-specific T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

Not yet recruiting·CChildren's National Research Institute·Phase 1·NCT07796061·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAA-T Cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TAA-T Cell. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Children's National Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: CChildren's National Research Institute

TAA-T Cell

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Diffuse Midline Glioma1 trial

References

Drug Info

Quick Facts

Related News